25 May 2016
OSE Pharma and Effimune announce the launch of a non-interventional study in hepatocellular carcinoma under a private-public collaborative program.
Paris, Nantes – May 19, 2016, 17:45pm – OSE Pharma SA (ISIN: FR0012127173; Ticker: OSE), an immuno-oncology company with a specific immunotherapy activating T lymphocytes, currently in a registration Phase 3 study, and Effimune, a biotech company specialized in immune regulation with clinical applications in autoimmunity, transplantation and immune-oncology, today announce the launch of a non-interventional study in patients with hepatocellular carcinoma (primary liver cancer). This study is a private-public research program supported by the French National Cancer Institute (INCa, Institut National du Cancer) and the Direction Générale de l’Offre de Soins (DGOS, the French access to healthcare services).